Evidence map›Paper›PMID 35561842›Full record

ReviewBiochemical pharmacology2022

Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging.

Michelle L Spruill, Mirjana Maletic-Savatic, Howard Martin, Feng Li, Xinli Liu

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Spatial Distribution of Brain PET Tracers by MALDI Imaging.Journal of the American Society for Mass Spectrometry · 2025
    Article
  8. Review
  9. Review
  10. Mass Spectrometry Imaging for Spatial Toxicology Research.Journal of mass spectrometry : JMS · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michelle L SpruillDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Mirjana Maletic-SavaticDepartment of Pediatrics, Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA.
Howard MartinSagis Diagnostics, Houston, TX, 77092, USA.
Feng LiCenter for Drug Discovery and Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030, USA; NMR and Drug Metabolism Core, Advanced Technology Cores, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: feng.li@bcm.edu.
Xinli LiuDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA. Electronic address: xliu65@central.uh.edu.
Baylor College of Medicine · USUniversity of Houston · US

Funding

Targeting sperm-specific proteins during meiosis and sperm morphogenesisP01HD087157 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MATZUK, MARTIN M. · 2017 to 2021
$6.2M
Imaging Mass Spectrometry for metabolome mappingR01GM120033 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LIU, ZHANDONG, MALETIC-SAVATIC, MIRJANA · 2017 to 2021
$2.5M
Mechanisms of Liver Toxicity of Anit-Depressant DuloxetineR01DK121970 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI LI, FENG · 2020 to 2023
$1.8M
Elucidating Chemical Features that Block or Facilitate Passage across the Blood-Testis and/or Blood-Epidydimal Barriers in MiceR33HD099995 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LI, FENG · 2022 to 2024
$1.7M
FOXA1 inhibitors to overcome endocrine resistance in ER+ breast cancerP20CA221731 · NCI · UNIVERSITY OF HOUSTON · PI CHOW, DIANA S-L. · 2018 to 2021
$1.1M
Pilot Project 1: Mexican immigrants' biological and behavioral cancer risk based on stressP20CA221696 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 2017 to 2020
$1.1M
Elucidating Chemical Features that Block or Facilitate Passage across the Blood-Testis and/or Blood-Epidydimal Barriers in MiceR61HD099995 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LI, FENG · 2020 to 2021
$862k
Novel Therapeutics Targeting HER2 Positive Breast Cancer Brain MetastasisR15CA182769 · NCI · UNIVERSITY OF HOUSTON · PI LIU, XINLI · 2015 to 2019
$523k
NCI NIH HHS P20 CA221696NCI NIH HHS P20 CA221731NCI NIH HHS R15 CA182769NICHD NIH HHS P01 HD087157NICHD NIH HHS R33 HD099995NICHD NIH HHS R61 HD099995NIDDK NIH HHS R01 DK121970NIGMS NIH HHS R01 GM120033
6 · The paper itself

Abstract

Mass spectrometry imaging (MSI) is emerging as a powerful analytical tool for detection, quantification, and simultaneous spatial molecular imaging of endogenous and exogenous molecules via in situ mass spectrometry analysis of thin tissue sections without the requirement of chemical labeling. The MSI generates chemically specific and spatially resolved ion distribution information for administered drugs and metabolites, which allows numerous applications for studies involving various stages of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET). MSI-based pharmacokinetic imaging analysis provides a histological context and cellular environment regarding dynamic drug distribution and metabolism processes, and facilitates the understanding of the spatial pharmacokinetics and pharmacodynamic properties of drugs. Herein, we discuss the MSI's current technological developments that offer qualitative, quantitative, and spatial location information of small molecule drugs, antibody, and oligonucleotides macromolecule drugs, and their metabolites in preclinical and clinical tissue specimens. We highlight the macro and micro drug-distribution in the whole-body, brain, lung, liver, kidney, stomach, intestine tissue sections, organoids, and the latest applications of MSI in pharmaceutical ADMET studies.

Indexed as

KidneyLiverLungMass SpectrometrySpatial AnalysisSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationDrug absorptionDrug distributionMass spectrometry imagingMSIPharmacokineticsToxicologyXenobiotic metabolism

Identifiers

PMID35561842
PMCPMC9744413
OpenAlexW4229451814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.